|
|
 |
|
| Overview |
| MACS GMP CD3 pure is a GMP-grade soluble CD3 (OKT3) antibody for ex vivo T cell activation. |
| Details |
Background information
The CD3 antibody (OKT3) recognizes the human CD3 antigen which is expressed on mature T cells, thymocytes and NKT cells. CD3 is associated with the T cell receptor (TCR) and induces the signaling cascade for effector functions of the T cell.
Activation and proliferation of T cells can be induced by interaction of the T cell receptor (TCR) with peptide-MHC complexes expressed on the surface of antigen presenting cells (APC). T cell activation can also be achieved by agonistic stimulation with the CD3 antibody binding to the TCR complex.
Applications
The antibody is suitable for ex vivo T cell activation and expansion and is already established in a variety of clinical protocols for ex vivo T cell stimulation. For example, the transduction of T cells with viral vectors requires the previous activation, which can be achieved by stimulation with CD3 antibody1,2. Furthermore, T cell subsets, such as tumor infiltrating lymphocytes (TILs) can be expanded3, or T cells polyclonally activated by CD3 stimulation.
The CD3 antibody can be combined with CD28 antibody, which gives an additional costimulatory stimulus4.
Quality statement
MACS GMP Products are manufactured and tested under a certified ISO 9001 quality system and in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.
No animal-, or human-derived materials were used for manufacture of these products. |
| Disclaimer |
| MACS GMP Products are for research use and ex vivo cell culture processing only, and are not intended for human in vivo applications. |
| Clone | Isotype |
| OKT3 | Mouse IgG2a |
| | |
|
|
| Favorites / Prices |
Request prices or add products to your favorite list.
|
| Details |
|
| Products |
| MACS GMP CD3 pure |
| Availability: Worldwide (1) |
- 0.2 mg (2)
Download datasheet
170-076-124
|
- 1 mg (3)
170-076-116
|
| (1) For availability in your country please contact your local representative. |
| (2) in 1 mL/vial |
| (3) in 1 ml/vial |
|
| References |
| 1. Pule et al. (2008) Nat. Med. 14 (11): 1264-1270. |
| 2. Ciceri et al. (2009) Lancet Oncol. 10 (5): 489-500. |
| 3. Dudley et al. (2005) J. Clin. Oncol. 23 (10): 2346-2357. |
| 4. Lamers et al. (2002) Cancer Gene Ther. 9 (7): 613-623. |
|
|
|
© 1999 - 2012 Miltenyi Biotec ¦ Terms & conditions ¦ Legal notes
|
